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ABSTRACT
Objective Natural killer (NK) cells are important
mediators of liver inﬂammation in chronic liver disease.
The aim of this study was to investigate why liver
transplants (LTs) are not rejected by NK cells in the
absence of human leukocyte antigen (HLA) matching,
and to identify a tolerogenic NK cell phenotype.
Design Phenotypic and functional analyses on NK cells
from 54 LT recipients were performed, and comparisons
made with healthy controls. Further investigation was
performed using gene expression analysis and donor:
recipient HLA typing.
Results NK cells from non-HCV LT recipients were
hypofunctional, with reduced expression of NKp46
(p<0.05) and NKp30 (p<0.001), reduced cytotoxicity
(p<0.001) and interferon (IFN)-γ secretion (p<0.025).
There was no segregation of this effect with HLA-C, and
these functional changes were not observed in
individuals with HCV. Microarray and RT-qPCR analysis
demonstrated downregulation of STAT4 in NK cells from
LT recipients (p<0.0001). Changes in the expression
levels of the transcription factors Helios ( p=0.06) and
Hobit (p=0.07), which control NKp46 and IFNγ
expression, respectively, were also detected.
Hypofunctionality of NK cells was associated with
impaired STAT4 phosphorylation and downregulation of
the STAT4 target microRNA-155. Conversely in HCV-LT
NK cell tolerance was reversed, consistent with the more
aggressive outcome of LT for HCV.
Conclusions LT is associated with transcriptional and
functional changes in NK cells, resulting in reduced
activation. NK cell tolerance occurs upstream of major
histocompatibility complex (MHC) class I mediated
education, and is associated with deﬁcient STAT4
phosphorylation. STAT4 therefore represents a potential
therapeutic target to induce NK cell tolerance in liver
disease.
INTRODUCTION
Liver transplantation (LT) is a successful procedure
despite being performed in the context of MHC
mismatching, and in comparison to other organ
transplants the doses of immunosuppression
required are relatively modest.1–3 Multiple studies
have demonstrated the relative tolerogenic micro-
environment of the liver to classical T cell mediated
immunity.4 However the liver is rich in cells of the
innate immune system and how tolerance operates
at the level of innate immunity is unknown.
Natural killer (NK) cells are cytotoxic innate
lymphocytes forming up to 30% of the intrahepatic
lymphocyte population. They are important media-
tors of liver damage in viral and inﬂammatory liver
disease.5–9 NK effector functions are controlled by
a balance of activating and inhibitory signals. Of
particular relevance to LT are the killer cell
immunoglobulin-like receptors (KIRs), which have
HLA class I ligands deﬁned by a KIR binding motif
at residues 77–80 of the HLA molecule. The KIR
can be either activating or inhibitory, but in the
context of transplantation it is the inhibitory recep-
tor interactions with HLA that dominate. In this
context it can be considered that NK cells are edu-
cated on recipient HLA class I, and if there is a mis-
match and the donor does not express the same
Signiﬁcance of this study
What is already known about this subject?
▸ Natural killer (NK) cell alloreactivity is well
described in bone marrow transplantation.
▸ As HLA matching is not employed in liver
transplantation (LT), NK cell mediated
alloreactivity is predicted after transplantation.
However LT does not require high levels of
immunosuppression.
▸ Previous studies have provided conﬂicting data
on the effect of HLA matching for NK cell
ligands in LT.
What are the new ﬁndings
▸ After LT, recipient NK cells exhibit a tolerant
phenotype, with downregulation of activating
receptors, reduced cytotoxicity and cytokine
production.
▸ NK cell tolerance is associated with
perturbation of the IL-12/STAT4 signalling
pathway
▸ There is no effect of HLA matching on NK cell
activation.
▸ NK cell tolerance is partially reversed in HCV
infection.
How might it impact on clinical practice in
the foreseeable future?
▸ Our data identiﬁes STAT4 as a therapeutic
target for inducing NK cell tolerance which may
be important for LT and autoimmune liver
disease.
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HLA ligands for inhibitory KIR as the recipient then alloreactiv-
ity should result. This is observed in haematopoietic stem cell
transplantation, in which clinically important NK cell alloreac-
tivity can affect outcome.10 Conversely, as LT is performed
without HLA matching there is a strong potential for NK cell
alloreactivity against the graft. However this is not observed
clinically.
Previous genetic studies have reported either neutral or
adverse effects of mismatching ligands for NK cells.11–14
Furthermore functional studies have not shed light on the
mechanisms of NK cell tolerance to the allograft. A limited
analysis detected changes in the frequencies of speciﬁc NK cell
subpopulations in the 1st week following transplantation.15 For
instance it has been shown that there is a reduction in the fre-
quency of NKp30-positive NK cells in children but not in
adults transplanted for HCV.16 17 Furthermore the effects of
calcineurin inhibitors on NK cell activity are not clear, with
studies showing either neutral or immunosuppressive effects in
vitro.18–22 Human NK cells originate in the bone marrow, but
can have some degree of maturation in the peripheral lymph-
oid tissue.23 As the liver is rich in immature CD56bright NK
cells this raises the possibility that NK cells may also mature in
the liver.24 Thus there are multiple levels at which NK cells
may be affected by LT.
The concept of NK cell tolerance, in general, and speciﬁcally
in the context of liver disease, is poorly understood. However
as NK cells interact directly with T cells and dendritic cells, they
may be important as a target to downregulate liver inﬂammation
in autoimmune liver disease, such as primary biliary cirrhosis in
which there is increased NK cell cytotoxicity.7 Therefore in
order to understand a potential mechanism for NK cell toler-
ance we have undertaken a cross-sectional study of individuals
following LT.
MATERIALS AND METHODS
Patient recruitment
The study was conducted according to the Declaration of
Helsinki. Patients were recruited from the outpatient clinics at
Kings College Hospital, London and St Mary’s Hospital,
London. Demographic and clinical data are detailed in table 1.
Lymphocyte phenotyping
Peripheral blood mononuclear cells (PBMCs) were isolated by
density gradient centrifugation and stored in liquid nitrogen.
Table 1 Demographic and clinical data
Transplants Healthy controls p Value
Total, n 54 31
Male, n (%) 32 (59.3) 18 (58.1) NS
Age, years (SD) 60 (9.47) 41 (13.4) <0.0001
Aetiology, n (%)
HCV 18 (33.3)
ALD 7 (13.0)
PSC 7 (13.0)
PBC 6 (11.1)
ALF 5 (9.3)
Cryptogenic/NASH 3 (5.6)
Subacute 2 (3.7)
AIH 1 (1.9)
Other 5 (9.3)
Time since LT, days (range) 2010 (103–7773)
Immunosuppression, n (%) (data missing from 2 patients)
Tacrolimus 43 (79.6)
Sirolimus 2 (3.7)
Ciclosporine 4 (7.4)
Corticosteroid 22 (40.7)
Mycophenolate 14 (25.9)
Unknown 2 (3.7)
Post-transplant biopsy available, n (%) 31 (57.4)
Episode of rejection, n (%) 5 (9.4)
Patients with HCV
Number treated for HCV, n (%) 5/18 (27.8)
Successful treatment, n (%) 0/5 (0)
Viraemic, n (%) 18/18 (100)
Mean viral load IU/mL (range) 3.59×106 (8.25×103–1.08×107)
Lab Data (range, SD)
AST, IU/L 38.6 (16–119, 25)
INR 1.1 (0.89–2.71, 0.49)
Albumin, g/L 39.9 (24–46, 4.6)
Bilirubin, μmol/L 11.4 (3–50, 8.6)
Platelets, ×109/L 236.9 (73–530, 105)
Tacrolimus level, ng/mL 5.11 (0.5–14.9, 2.7)
ALD, alcohol-related liver disease; AIH, autoimmune hepatitis; ALF, acute liver failure; AST, aspartate transaminase; INR, international normalised ratio; NASH, non-alcoholic
steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
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NK cell puriﬁcation was performed with the Dynabeads
Untouched Human NK cells kit (Life Technologies, Paisley, UK).
Antibodies used were: CD56-PECy7, CD3-PerCP,
CD16-APC-Cy7, CD57-Paciﬁc Blue (all BioLegend, San Diego,
USA), CD56-ﬂuorescein isothiocyanate (FITC) (BD Biosciences,
Oxford, UK), CD3-Paciﬁc Blue (eBioscience, Hatﬁeld, UK),
CD158a,h-PE, CD158b-FITC, CD158b1/b2,j-PE (all Beckman
Coulter, Marseille, France), NKp30-APC, NKp46-APC,
NKG2D-APC (all Miltenyi Biotec, Gladbach, Germany),
NKG2C-PE, NKG2C-PerCP, NKG2C-APC (all R&D Systems
Europe, Oxford, UK), rabbit STAT4 (Invitrogen, Paisley, UK)
with goat anti rabbit secondary-APC (Abcam, Cambridge, UK).
Functional assays
Degranulation and intracellular cytokine assays
PBMCs were stimulated overnight with 1 ng/mL interleukin (IL)
15 (R&D). These were then incubated with K562 cells at an
Effector:Target (E:T) ratio of 10:1 in the presence of
CD107a-AF647 antibody (eBioscience), with Golgi Stop (BD
Biosciences) and stained with CD3-Paciﬁc Blue and
CD56-PECy7 or with anti-interferon (IFN)γ-FITC and antitu-
mour necrosis factor (anti-TNF)α-PE (BioLegend).
Cytotoxicity assay
PBMCs were stimulated with 1 ng/mL IL-15, and incubated
with K562 cells, prelabelled with CellTracker Orange (Life
Technologies), at an E:T ratio of 5:1. K562 cells without
effector cells were used as a control. The cells were stained with
Live/Dead ﬁxable far-red stain (Life Technologies) and analysed
by ﬂow cytometry. Speciﬁc killing of the target cells was calcu-
lated as follows:
%Live K562=Dead K562 in test wells
%Live K562=Dead K562 in control wells
Intracellular pSTAT assay
PBMCs were stimulated with 10 ng/mL IL-12 for 60 min.
pSTAT4 was measured using the Phosﬂow kit (BD Biosciences)
according to the manufacturer’s protocol.
Immunosuppression assays
PBMCs from healthy donors were incubated in 10% fetal calf
serum (FCS) in Roswell Park Memorial Institute (RPMI) 1640
(Biowhittaker, UK) with 1% penicillin/streptomycin, 2 mM glu-
tamine supplemented with 1 ng/mL IL-15, and either tacrolimus
(FK506), ciclosporine A or prednisolone (all Sigma Aldrich,
Dorset, UK) at the indicated concentrations.
HLA and KIR genotyping
These were performed as previously described.25 26
Microarray
RNA was extracted from puriﬁed NK cells using TRIzol
(Invitrogen, Paisley, UK). Hybridisation was performed accord-
ing to the Agilent 60-mer oligo microarray (Agilent
Technologies, Santa Clara, USA). Fluorescence signals of the
hybridised Agilent microarrays were detected using Agilent’s
Microarray Scanner System (Agilent Technologies). The Agilent
Feature Extraction Software was used to process the microarray
image ﬁles. Pathway and functional analyses were performed
using Ingenuity Pathway Analysis V.6.0 (Ingenuity Systems,
http://www.ingenuity.com). Microarray data are available in the
ArrayExpress database under accession number E-MTAB-2132
(http://www.ebi.ac.uk/arrayexpress).
Quantitative real time reverse transcription PCR
RNA was extracted from puriﬁed NK cells and the expression
of candidate genes was analysed using a custom array plate with
wells preloaded with primers (RT2 proﬁler PCR array, Qiagen,
UK). Expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and smooth muscle actin (SMA) was assayed for com-
parative quantitation. MicroRNA-155 (miR-155) quantitative
PCR was performed with the miScript PCR system (Qiagen)
according to the manufacturer’s instructions. Human RNU6B
(RNU6-2) miScript primers were used for normalisation con-
trols. Reaction mixes were prepared in triplicate.
Statistical analysis
Statistical analysis was performed by two-tailed Student’s t test or
one-way analysis of variance (ANOVA) as appropriate using
GraphPad Prism 6 (GraphPad Software, La Jolla, USA). Analyses
of the microarray gene expression data were performed with the
software environment R together with packages available as part
of the Bioconductor project (http://www.bioconductor.org). Raw
data was quality assessed using scatter plot matrices, box plots
and principal components analysis. Replicate probes were mean
summarised and quantile normalised using the preprocess Core R
package. The limma R package27 was used to compute empirical
Bayes moderated t statistics to identify differentially expressed
genes between groups. A corrected p value cut-off of <0.05 was
used to determine signiﬁcant differential expression. The average
power for the analysis was 0.81, varying between 0.40 (for lyso-
some associated membrane protein (LAMP) assays) and 0.99 (for
natural cytotoxicity receptor (NCR) expression) for signiﬁcance
at the 5% level.
RESULTS
Downregulation of activating receptors on NK cells in
non-HCV transplant recipients
NK cell phenotyping was performed on PBMCs from 54 LT
individuals and 31 healthy controls. As chronic HCV infection
can affect NK cell phenotype and function we divided the
cohort into those transplanted for HCV (n=18) and those for
other diseases (n=36) (table 1). NK cells were divided into
CD56bright and CD56dim subsets and expression of the activat-
ing receptors NKp30, NKp46 and NKG2D analysed (ﬁgure 1).
The proportion of CD56bright NK cells was increased in the LT
cohort as compared with healthy controls (15% vs 8%,
p<0.001). This was observed in the HCV positive (19% vs 8%,
p<0.001) and non-HCV (13% vs 8%, p=0.011) recipients
(ﬁgure 1A). The increase in CD56bright NK cells in HCV versus
non-HCV LT (19% vs 13%, p=0.012) is consistent with previ-
ous studies of NK cells in non-transplant chronic HCV
infection.28
We found that NKp30 and NKp46, but not NKG2D, were
downregulated on NK cells post LT (NKp30 p<0.001,
NKp46 p<0.05, ﬁgure 1B, C) and that this was conﬁned to
individuals not transplanted for HCV infection. Furthermore
downregulation was more notable on the CD56dim subset of
NK cells, with NKp30 downregulated more than 50% (ﬁgure
1D, E). There was no difference in NCR expression on
CD158a and CD158b expressing NK subsets, suggesting that
the effects seen are not be related to HLA-C allospeciﬁcity
(see online supplementary ﬁgure S1). The disparate ﬁndings
for NK cells in HCV and non-HCV LTs are consistent with
observations of upregulation of NK cell activating receptors
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in chronic HCV infection in untransplanted individuals and
previous work in individuals transplanted for HCV-associated
cirrhosis.17 29–31
NK cells in LT recipients are hypofunctional
To determine if the downregulation of NKp30 and NKp46 had
a functional correlate we measured the killing capacity of NK
cells from the LT recipients against MHC class I deﬁcient
targets. NK cells were stimulated with IL-15 and K562 targets,
which express the ligand for NKp30.30 These assays demon-
strated that K562 killing (p<0.001) and degranulation as deter-
mined by CD107a expression (p=0.035), were both impaired
in the non-HCV, but not HCV-positive, recipients (ﬁgure 2A, B).
Similarly we found an impairment of IFNγ production in these
individuals compared with controls (p=0.02, ﬁgure 2C).
Although we observed a trend towards lower levels of TNFα
secretion, this did not reach statistical signiﬁcance (ﬁgure 2D).
These functional data are consistent with chronic HCV infection
overcoming LT-associated NK cell tolerance and the associated
poorer outcome of LT for untreated HCV as compared with
non-viral causes.
To investigate if the NK cell changes observed in vivo were
related to the direct effects of immunosuppressive medication,
we determined the effects of tacrolimus, ciclosporine A and
prednisolone on the phenotype and function of NK cells, from
ﬁve healthy donors. We observed minor effects of prednisolone
on NKG2D and NKp30 expression, and of ciclosporine on
NKG2D expression (see online supplementary ﬁgure S2).
However there were no changes in cytotoxicity. Furthermore, in
the patient cohort, length of immunosuppression (or time since
transplant) was not associated with NCR expression, NK func-
tion or advanced ﬁbrosis (see online supplementary ﬁgure S3).
These data imply that our observations of NK cells in LT in
vivo are not a direct effect of immunosuppression on mature
NK cells, but are most likely related to changes affecting devel-
oping NK cells, as they develop from CD56bright to CD56dim.
HLA-C mismatch does not inﬂuence recipient NK cell
alloreactivity
We next investigated if mismatching at HLA-C affected NK cell
reactivity by comparing expression of activating receptors on
NK cells expressing KIR with a ligand present in both the recipi-
ent and donor (matched) versus those with KIR for a ligand in
the recipient, but not the donor (mismatched) (ﬁgure 2E, F).
There was no difference in activating receptor expression
between matched and mismatched groups (ﬁgure 2E). Similarly
there was no effect of HLA-C matching on CD107a degranula-
tion (ﬁgure 2F). Thus in our cohort HLA-C mismatching does
not affect expression of natural cytotoxicity receptors, or NK
cell activity, implying that NK cell tolerance is occurring
upstream of MHC-dependent education or ‘licensing’.
NK cell STAT4 gene expression is downregulated in LT
To investigate potential mechanisms of NK cell tolerance in LT
we performed a whole genome microarray experiment, compar-
ing gene expression in NK cells between LT non-HCV, LT HCV
and healthy controls (n=4 in each group). Over 800 genes were
differentially expressed between the three groups (ﬁgure 3A).
Eleven signiﬁcant candidate genes were chosen from the micro-
array data for validation by quantitative RT-PCR in 13 healthy
Figure 1 Phenotypic changes in natural killer (NK) cells post liver transplantation (LT). (A) CD3−/CD56+ NK cells were gated and separated into
CD56dim (left-hand square) and CD56bright (right-hand square) subpopulations prior to analysis. The percentage of CD56bright NK cells is shown in
the bar chart. (B) Representative histogram plots demonstrating the mean ﬂuorescence intensity (MFI) of the activating receptors in patients with
HCV and non-HCV LT (ﬁlled histograms) as compared with healthy controls (open histograms). (C–E) Comparison of expression of NKp30, NKp46
and NKG2D on total NK cells (C) and CD56dim (D) and CD56bright (E) NK subsets. For all charts mean and SEM are shown (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001).
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Figure 2 Hypofunctional natural killer (NK) cells in liver transplantation (LT). (A) Flow cytometry cytotoxicity assays using puriﬁed NK cells and K562
targets. Representative CellTracker Orange (CTO) staining of the target cells (far left panel), and cytotoxicity assays (middle panels) from each patient
group are shown and the results from 14 LT non-HCV, 9 LT HCV and 22 healthy donors are charted (right). (B–D) Flow cytometry plots (left panels) and
summary of CD107a degranulation assays (B), interferon (IFN)-gamma secretion (C), and tumour necrosis factor (TNF)-α secretion (D). (E) Effect of
HLA-C matching on expression of activating receptors on NK cells. Grey bars (▪) indicate expression on NK cells expressing an inhibitory killer cell
immunoglobulin-like receptor (KIR) for the donor HLA-C and black bars (▪) NK cells expressing a KIR without a ligand in the donor liver. (F) Comparison
of CD107a degranulation on matched or mismatched NK cells. For all graphs means and SEM are shown (*p<0.05, **p<0.01, ***p<0.001).
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controls, 17 LT non-HCV, and 12 LT HCV (ﬁgure 3B).
Signiﬁcant ﬁndings are shown in table 2. The most consistent
difference between LT and healthy controls was a downregula-
tion of STAT4 gene expression. This occurred in both LT groups
compared with healthy controls (p=0.0004, −10.73-fold differ-
ence, and p=0.01, −3.78-fold difference in LT non-HCV and
LT HCV, respectively). Compared with controls, in LT
non-HCV there was also upregulation of ZNF683 (Hobit, a
repressor of IFNγ expression,32 p=0.06, 2.03-fold difference)
and downregulation of KIR2DS3 (p=0.05, −2.14-fold differ-
ence). The only candidate gene differentially expressed with
near signiﬁcance between LT HCV and LT non-HCV was
IF144L (an IFN induced protein, p=0.07, 3.14-fold upregula-
tion in HCV, consistent with the activation of IFN stimulated
genes found in chronic HCV infection33). When comparing all
LTs (HCV and non-HCV) with controls, downregulation of
STAT4 (p=0.0001, −6.97-fold difference) and IKZF2 (p=0.06,
−2.26-fold difference) and upregulation of ZNF683 (p=0.07,
2.10-fold difference) were found. IKZF2, also known as Helios,
is a transcription factor of the Ikaros family speciﬁcally asso-
ciated with NKp46 expression.34 Thus we have observed a
trend towards the downregulation of NK cell cytotoxicity and
cytokine secretion being determined at a transcriptional level.
However, we found no difference in basal STAT4 levels by
ﬂow cytometry, and the Ingenuity Pathway Analysis indicated an
effect on JAK/STAT signalling (see online supplementary ﬁgure
S4). We therefore assessed STAT4 function following stimulation
of lymphocytes by IL-12. After IL-12 stimulation, there was sig-
niﬁcantly lower STAT4 phosphorylation in LT recipients com-
pared with healthy controls (p<0.001) (ﬁgure 3C–E). Thus these
data demonstrate a functional deﬁciency in IL-12 signalling
related to potentially low levels of an active isoform of STAT4.
In order to exclude this effect as being directly due to immuno-
suppressive medication we tested the effects of tacrolimus, ciclos-
porine A and prednisolone on IL-12 induced STAT4
phosphorylation. We observed no change in STAT4 phosphoryl-
ation following incubation with immunosuppressants (ﬁgure 3F).
Thus the tolerant NK cell phenotype is associated with defective
STAT4 signalling, and this is not related to the direct effect of
immunosuppression on mature NK cells.
In addition to controlling NK cell activation, STAT4 is also
thought to control NK cell differentiation through
miR-155.35 36 Quantitative RT-PCR performed on puriﬁed NK
cells from patients post LT and healthy controls demonstrated a
4.9-fold downregulation of miR-155 in LT compared with
healthy controls (p=0.04, ﬁgure 4A). This is consistent with
our observed defect in STAT4 signalling. Thus the effects of
STAT4 downregulation have an ongoing effect on NK cells in
post-transplant patients. In mice miR-155 is associated with
accelerated NK cell maturation, and deletion of this miRNA has
been shown to result in defects in NK cell maintenance and
homoeostasis.36 We therefore investigated whether equivalent
deﬁcits are observed in human LT recipient NK cells by assessing
NK cell maturity using the markers CD16, CD57 and NKG2C.
These markers have been shown to be associated with terminal
differentiation of NK cells and a ‘memory’ phenotype.37 38 We
found no difference in expression of CD16 or CD57 between
LT recipients and healthy controls, and speciﬁcally no difference
in CD57 expression on CD56dimCD16+ NK cells between the
groups (ﬁgure 4B–D). This indicates that the low levels of cyto-
toxicity observed post LT is not related to accumulation of the
hypofunctional CD57+CD16+ NK cell subset. However, a sig-
niﬁcantly greater proportion of NK cells expressed NKG2C in
LT non-HCV only (p=0.019). There was also greater NKG2C
Figure 3 STAT4 gene expression and signalling is altered after liver transplantation (LT). (A) Venn diagram of differentially expressed genes by
microarray. Bold type indicate the number of genes differentially expressed between two groups only, and intersections indicate the numbers of
genes differentially expressed in common between two or three sets of groups. (B) Clustergram depicting gene expression of candidate genes
evaluated by qRT-PCR (HC, healthy control; LTC, HCV LT; LT, non-HCV LT) (C) Summary of basal STAT4 levels in natural killer (NK) cells from LT
recipients (n=7) and HCs (n=7) as determined by ﬂow cytometry. The mean ﬂuorescence intensity of STAT4 is plotted. (D) Representative ﬂow
cytometry histograms showing interleukin (IL) 12 stimulated pSTAT4 staining in patients with LT and HCs. (E) Summary of pSTAT levels in eight LT
and eight control individuals. (F) IL-12 stimulated pSTAT4 levels in peripheral blood mononuclear cells (PBMCs) from three healthy donors when
incubated with immunosuppressive drugs for 48 h. Charts show means, SEM and p values <0.05. CysA, ciclosporine; pred, prednisolone.
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expression in CD56bright and CD56dim subsets in both LT
groups versus controls (ﬁgure 4E). As NKG2C expression has
previously been associated with CMV infection,38 we compared
NKG2C between CMV seropositive and seronegative indivi-
duals within our cohort. There was no signiﬁcant difference
between the two groups although there was a trend towards an
increase in the CMV seropositive group (14% vs 8% in CMV+
and CMV−, respectively, p=0.38, ﬁgure 4F). Thus the increase
observed in NKG2C may in part be related to the effects of
CMV, but overall we found no speciﬁc changes in receptor
expression that reﬂect altered maturation of the CD56dim NK
cell subset. Thus overall our data are consistent with changes in
NK cells occurring upstream of full functional maturation of
NK cells, potentially at the transition between CD56bright and
CD56dim NK cells.
DISCUSSION
We provide an analysis of human NK cells in LT demonstrating
changes in phenotype, function and mRNA expression. This tol-
erant NK cell phenotype has not been previously described and
is important in explaining tolerance to liver allografts, but may
Table 2 qRT PCR analysis for the candidate genes identified by microarray analysis
All LT vs HC LT non-HCV vs HC LT HCV vs HC LT HCV vs LT non-HCV
Symbol Fold difference p Value Fold difference p Value Fold difference p Value Fold difference p Value
STAT4 −6.97 0.0001 −10.73 0.0004 −3.78 0.01 2.84 ns
IKZF2 −2.26 0.06 −2.88 ns −1.61 ns 1.79 ns
ZNF683 2.10 0.07 2.03 0.06 2.20 ns 1.08 ns
IF144L 1.99 ns 1.14 ns 4.38 ns 3.85 0.07
KIR2DS3 −2.47 ns −2.14 0.05 −3.01 ns 0.71 ns
Bold values indicate p<0.05.
HC, healthy control; LT, liver transplantation.
Figure 4 Changes in natural killer (NK) cell maturation markers after liver transplantation (LT). (A) The relative miR-155 level in NK cells from LT
recipients (n=7) compared with healthy controls (HCs, n=7) as determined by RT-PCR (means and SEM are shown). (B–F) Comparison of of
expression of CD16 on CD56+ NK cells (B), CD57 on CD56+ NK cells (C), CD57 on CD56Bright and CD56Dim NK cells (D) and NKG2C on CD56Bright
and CD56Dim NK cells (E) in LT non-HCV (n=20), LT HCV (n=8), and healthy controls (n=14). Charts show mean values and SEM (*p<0.05). (G)
Expression of NKG2C on CD56+ NK cells from CMV seropositive (n=14) and CMV seronegative (n=9) LT recipients (ns=non-signiﬁcant). CMW,
cytomegalovirus.
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also have relevance for autoimmune liver disease in which indu-
cing tolerance represents a therapeutic option. Importantly it is
signiﬁcantly different from other transplants, such as stem cell
transplantation in which NK cell alloreactivity is observed,39
and is consistent with the unique tolerogenic environment of
the liver. One possibility accounting for this tolerance is that
immature NK cells undergo a maturation step within the liver,
as occurs in secondary lymphoid tissue, and that this maturation
step is altered by the cytokine microenvironment of the liver.
Interestingly, changes in miR155 and NKG2C suggest an effect
on NK cell maturation in this context. However, further import-
ant insights into this process could be gained by the study of
intrahepatic NK cells.
We observed transcriptional level changes in LT, the most signiﬁ-
cant of which was STAT4 downregulation (table 2 and ﬁgure 3).
This was not associated with changes in total STAT4 levels as
determined by ﬂow cytometry. A lack of correlation between
protein and mRNA levels can be related to lower rates of protein
as compared with mRNA turnover.40 However STATs exist in
several different isoforms, including C terminally truncated var-
iants of the mature protein, which act as dominant negatives.41–44
As the primers for the qPCR were against the 3’ region of STAT4
then potentially the qPCR assay and the ﬂow cytometry assay
could be detecting different and non-functional or potentially
dominant negative isoforms. Conversely, in the microarray experi-
ment we did not observe changes in molecules that directly
control STAT4 function such as SOCS3. Thus further investigation
of STAT4 isoforms would be an important area for study of the
role of STAT4 in lymphocyte signalling.
In immunogenetic studies STAT4 has been implicated in
primary biliary cirrhosis and autoimmune hepatitis.45 46 In
genome wide association study (GWAS) studies STAT4 and
IL-12 single nucleotide polymorphism (SNPs) are associated
with primary biliary cirrhosis with extremely high probabilities
(both <10−18), consistent with this being a key axis in liver
inﬂammation and tolerance.47 Similarly STAT4 regulates
downregulation of miR155, which is associated with impaired
NK cell memory and antiviral responses.36 The importance of
adaptive or ‘memory’ NK cell responses are being increasingly
recognised.37 38 Long-lasting memory NK cells have the ability
to expand rapidly on repeated exposure to the viral infection.
Interestingly this mechanism has been shown to be dependent
on IL-12 and STAT4, and deﬁciencies in either of these results
in diminished memory cell expansion.48 Therefore, as LT is
associated with diminution in IL-12/STAT4 signalling, there
may be a similar dysfunction in the generation of longer-lasting
memory cells, contributing to the observed hypofunctionality.
This could have a beneﬁcial effect in relation to graft tolerance,
and a detrimental effect on susceptibility to pathogens, consist-
ent with the accelerated disease progression observed after
transplantation for HCV, and for HBV in the prenucleoside
era. Furthermore elevated pSTAT4 is associated with a beneﬁ-
cial response to HCV treatment and STAT4 polymorphisms
have been associated with accelerated liver ﬁbrosis following
transplantation.49–51 Thus STAT4 is a key molecule controlling
NK cells in liver inﬂammation and as NK cells can crosstalk
with cells of the adaptive immune system, inducing an NK
cell tolerant phenotype may be beneﬁcial in suppressing
autoimmunity.
Conversely in HCV infection NK cells are less tolerant with
relatively normal levels of NKp30 and NKp46 expression, and
preservation of cytotoxicity and cytokine secretion (ﬁgures 1
and 2). Previous work has demonstrated upregulation of NKp46
in chronic HCV infection29 52 53 and one study has correlated
higher levels with more severe disease severity.30 This suggests
that HCV infection is counteracting the effects of downregula-
tion associated with LT. However the downregulation of STAT4
in HCV-LT NK cells indicates that HCV infection circumvents,
rather than prevents, NK cell tolerance. Speciﬁcally in HCV
infection IFNα-stimulated NK cell STAT4 phosphorylation is
downregulated with preservation of other pathways.54 Using the
K562 cell line we were able to test the NKp30 pathway and this
appears to have circumvented the observed STAT4
downregulation.
We used K562 cells in combination with IL-15 in assays of
NK cell function to assess whether receptor downregulation
leads to a functional defect. As K562 expresses ligands for
NKp30 and NKG2D, which signal via CD3ζ or FcεRIγ, this
assay bypasses the defect in STAT4 observed by us in this study,
and others in studies of non-transplant HCV.49 54 Thus we
observed a downregulation of STAT4 mRNA in our patients
with HCV LT as compared with healthy controls, but observed
normal levels of IFNγ secretion (ﬁgures 2 and 3). In order to
further understand the alterations in NK cell functions, and
their complex relationship with the discrete effects of trans-
plantation and HCV infection, the study of additional pathways
including IFNα and IL-18 would be valuable. However our
ﬁndings do suggest that several pathways are likely to be
affected, as in the patients with non-HCV transplant we have
observed hypofunctionality related to receptor-mediated and
IL-15 stimulation (ﬁgure 2).
The effect on NK cells of immunosuppressive drugs used in
transplantation is controversial with investigations to date
reporting conﬂicting results.20 55 However in our experiments
neither the phenotypic nor the functional ﬁndings observed in
recipient LT were recapitulated. While there are limitations to
these short-term incubation experiments, it is unlikely that the
effects we observed in vivo are related to the direct effects of
immunosuppressants on mature NK cells. More likely they are
due to the complex effects of LT and immunosuppression on
NK cell maturation during the CD56bright to CD56dim transi-
tion rather than later stage NK cell maturation as we did not
observe signiﬁcant changes in frequencies of CD16 or CD57+
NK cells. These changes likely occur prior to the acquisition of
inhibitory receptors for HLA-A, HLA-B and HLA-C.
Consistent with this we did not observe any relationship
between expression of inhibitory receptors, HLA-C and hypo-
functionality. Thus in LT it is unlikely that tolerance of NK
cells to the allograft is mediated by KIR:HLA-C interactions,
but occurs at a stage prior to the acquisition of KIR. As the
phenotypic and functional changes were largely seen in
CD56dim NK cells, but were not restricted to NK cells expres-
sing mismatched KIR, our data suggest that recipient NK cells
are ‘disarmed’ in a KIR-ligand independent manner. NK cells
comprise a higher percentage of the lymphocyte population
within the liver compared with the peripheral population and
there is increasing evidence that a high proportion of these are
phenotypically immature.56 57 We therefore propose that
immature recipient NK cells become ‘tolerised’ by undergoing
an altered maturation process during contact with the allograft,
which may be related to immunosuppression affecting the liver
cytokine microenvironment or NK cell maturation. Our ﬁnd-
ings suggest impairment of IL-12 signalling as a potential
mechanism for this. While these effects require further investi-
gation, our characterisation of recipient NK cell hypofunction-
ality provides an insight into the observed tolerability of liver
allografts and a model for future studies into NK cell alloreac-
tivity in solid organ transplantation.
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